Key result
Maternal IGF-I concentrations >400 ng/ml at delivery were found in all six cases of neonatal septal hypertrophic cardiomyopathy, compared to a mean of 302 ng/ml in control mothers.
Why the study?
Do maternal serum IGF-I levels predict the occurrence of neonatal septal hypertrophic cardiomyopathy in infants of mothers with diabetes?
Cohort (n=100)
Do maternal serum IGF-I levels predict the occurrence of neonatal septal hypertrophic cardiomyopathy in infants of mothers with diabetes?
Increased maternal serum IGF-I concentrations at delivery correlate with the occurrence of neonatal septal hypertrophic cardiomyopathy in infants of diabetic mothers.
No takes yet. Share an insight, caveat, or question.
Should not yet change monitoring in diabetic pregnancies; supports further investigation of maternal IGF-I as a neonatal septal HCM biomarker.
Cheah et al. (2004) conducted a cohort in Diabetes in pregnancy (n=100). Maternal serum IGF-I concentration vs. Control mothers (without diabetes) was evaluated on Neonatal septal hypertrophic cardiomyopathy. Maternal IGF-I concentrations >400 ng/ml at delivery were found in all six cases of neonatal septal hypertrophic cardiomyopathy, compared to a mean of 302 ng/ml in control mothers.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: